Phase Forward, a provider of data management solutions for clinical trials and drug safety, pointed to a growing list of customers adopting its Empirica Trace safety solution over the past year for comprehensive adverse event management. Among others, customers such as Thallion Pharmaceuticals, Panacea Pharmaceuticals, Inc., Bavarian Nordic A/S, Alapis S.A, and the International Institute for the Safety of Medicines Ltd. (ii4sm) are turning to Empirica Trace to efficiently capture and manage spontaneous report data across the full product life cycle, from clinical development through post-marketing.
Empirica Trace product is meeting a need across organizations of all sizes and therapeutic areas for a comprehensive safety solution by providing a fundamental building block for efficiently capturing and managing adverse event data.
The Empirica Suite of products is Phase Forward’s complete solution set for pharmacovigilance and risk management. In addition to the Empirica Trace product, the suite includes Empirica Study, which provides a dynamic visual data environment for reviewing safety data and detecting signals in trial data, and the Empirica Gateway E2B submission product which offers full support for E2B submission of case reports to regulators, affiliates and partners and receipt of data via E2B standard files. The suite also includes Empirica Signal, a data mining and signal management product. It provides detection and quantification of safety signals through the use of advanced data mining techniques that can be applied to any spontaneous reporting database.
